Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction
Authors:
- 20 September 2008
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 102 (8) , 933-937
Abstract
Erectile dysfunction (ED) is becoming an increasingly common problem and although oral therapies offer first‐line treatment for many men, they are contraindicated or ineffective in substantial groups of patients. Intracavernosal injection (ICI) therapy is the most effective nonsurgical treatment for ED and offers an effective alternative to oral therapy. Sufficient arterial blood supply and a functional veno‐occlusive mechanism are prerequisites in the attainment and maintenance of a functional erection. Invicorp ® (Plethora Solutions, London, UK) is a combination of vasoactive intestinal polypeptide (VIP) 25 µg and phentolamine mesylate 1 or 2 mg for ICI in the management of moderate to severe ED. The two active components have complementary modes of action; VIP has a potent effect on the veno‐occlusive mechanism, but little effect on arterial inflow, whereas phentolamine increases arterial blood flow with no effect on the veno‐occlusive mechanism. Clinical studies showed that Invicorp is effective in ≥80% of men with ED, including those who have failed to respond to other therapies and, unlike existing intracavernosal therapies, is associated with a very low incidence of penile pain and virtually negligible risk of priapism. We estimate that there are >5.9 million men in the USA alone for whom oral ED drugs are not a viable treatment option, and for whom Invicorp might offer a safe and effective alternative.Keywords
This publication has 25 references indexed in Scilit:
- CHAPTER 1: THE MANAGEMENT OF ERECTILE DYSFUNCTION: AN AUA UPDATEJournal of Urology, 2005
- Current perspectives on intracavernosal pharmacotherapy for erectile dysfunctionInternational Journal Of Impotence Research, 2000
- New therapies and delivery mechanisms for treatment of erectile dysfunctionInternational Journal Of Impotence Research, 2000
- ImpotenceJAMA, 1993
- The Role of Vasoactive Intestinal Polypeptide as a Neurotransmitter in Canine Penile Erection: A Combined in Vivo and Immunohistochemical StudyJournal of Urology, 1987
- Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in man per seWorld Journal of Urology, 1987
- DECREASE OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN THE PENISES FROM IMPOTENT MENThe Lancet, 1984
- Intracavernous Injection of Papaverine as a Diagnostic and Therapeutic Method in Erectile FailureAngiology, 1984
- Vasoactive intestinal polypeptide (vip) as a putative neurotransmitter in penile erectionLife Sciences, 1983
- Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erectionActa Physiologica Scandinavica, 1981